An Exploratory Investigation of a Supplement to Promote Brain Health
1 other identifier
interventional
40
1 country
1
Brief Summary
Providing a combination of synergistic dietary supplements, such as vitamins B6, B12, and folate, as well as curcumin, lemon balm, and American ginseng is hypothesized to promote brain health and aid with brain fog, mental clarity, ability to handle stress, mood, focus, and productivity, as well as promote overall well-being.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 15, 2022
CompletedFirst Submitted
Initial submission to the registry
August 26, 2022
CompletedFirst Posted
Study publicly available on registry
August 29, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2022
CompletedApril 3, 2024
April 1, 2024
5 months
August 26, 2022
April 1, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Perceived changes in mental health symptoms as measured by Questionnaires
Questionnaires measure perceived changes in mental health symptoms (e.g., anxiety levels, mental clarity) and stress management on a scale of 0 (low levels of mental health symptoms) to 10 (very high levels of mental health symptoms)
31 days
Perceived changes in stress management as measured by Questionnaires
Questionnaires measure perceived changes in stress management on a scale of 0 (poor ability to manage stress) to 10 (excellent ability to manage stress)
31 days
Secondary Outcomes (1)
Changes in Cognitive Functioning
31 days
Other Outcomes (1)
Changes in plasma/serum biomarkers associated with brain health
31 days
Study Arms (1)
The Daily Supplement
EXPERIMENTALParticipants will use test product daily, and complete Biomarker assessments (at 1st dose, Day 7, Day 31), as well as surveys (at 1st dose, Day 7, Day 31), and Cognitive battery Assessments (at 1st dose, Day 7, Day 31).
Interventions
The ingredient list of the product includes the following: 400mg of curcumin (Longvida) 300mg of lemon balm extract (Cyracos) 200mg of American ginseng (Cereboost) 50mg of epigallocatechin gallate derived from green tea Organic oat milk powder Phosphatidylserine (SerinAid) (active) B6 (in the form of P5P) Folate (Quatrefolic) B12 Silica (non-active)
Eligibility Criteria
You may qualify if:
- In good general health with no major chronic conditions (e.g., diabetes, coronary heart disease, etc.)
You may not qualify if:
- Females who are pregnant or breastfeeding
- Anyone currently taking other supplements
- Anyone with a known allergic reaction
- Previous head trauma
- Anyone with chronic diseases such as diabetes, coronary heart disease, or cancer.
- Any psychological, mental, or neurodevelopmental disorders
- Consumes nicotine or marijuana in any form
- Previous or current alcohol addiction
- Consume more than 10 drinks per week
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Parablelead
- Citruslabscollaborator
Study Sites (1)
Citruslabs
Santa Monica, California, 90404, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher Hill, PhD
Citruslabs
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 26, 2022
First Posted
August 29, 2022
Study Start
June 15, 2022
Primary Completion
October 30, 2022
Study Completion
October 30, 2022
Last Updated
April 3, 2024
Record last verified: 2024-04